Gemcitabine anticancer activity enhancement by water soluble celecoxib/sulfobutyl ether-β-cyclodextrin inclusion complex

被引：40

作者：

Rescifina, Antonio ^{[1
]}

Surdo, Emanuela ^{[2
]}

Cardile, Venera ^{[3
]}

Avola, Rosanna ^{[3
]}

Graziano, Adriana Carol Eleonora ^{[3
]}

Stancanelli, Rosanna ^{[2
]}

Tommasini, Silvana ^{[2
]}

Pistara, Venerando ^{[1
]}

Ventura, Cinzia Anna ^{[2
]}

机构：

[1] Univ Catania, Dept Drug Sci, Vle A Doria 6, I-95125 Catania, Italy

[2] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Vle F Stagno Dalcontres 31, I-98166 Messina, Italy

[3] Univ Catania, Dept Biomed & Biotechnol Sci, Via Santa Sofia 97, I-95125 Catania, Italy

来源：

CARBOHYDRATE POLYMERS | 2019年 / 206卷

关键词：

Celecoxib; Sulfobutyl-ether-beta-cyclodextrin; Gemcitabine; NMR spectroscopy; Computational studies; In vitro biological studies; CELL LUNG-CANCER; IN-VITRO; PHASE-II; PHYSICOCHEMICAL CHARACTERIZATION; ANTIINFLAMMATORY ACTIVITY; EQUILIBRIUM-CONSTANTS; DOWN-REGULATION; FORCE-FIELDS; CELECOXIB; DOCETAXEL;

D O I：

10.1016/j.carbpol.2018.11.060

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

We investigated the complexation of celecoxib (CCB) into sulfobuthyl-ether-beta-cyclodextrin (SBE-beta 1-CD) for the realization of an inhalable dry-powder formulation containing gemcitabine (GEM) for lung anticancer therapy. Complexation increased the water solubility of CCB (0.003 mg/mL and 0.834 mg/mL for CCB free and complexed, respectively) and produced a quantitative dissolution of the drug within 15 min. The CCB/SBE-beta-CD inclusion complex showed a high stability constant (8131 M-1) not influenced by the presence of GEM in solution. Two-dimensional NMR experiments and computational studies demonstrated that the pyrazole ring of CCB penetrates deeper into SBE-beta-CD from the secondary rim. The aromatic rings are positioned at the edge of the cavity, establishing hydrogen bonds with the SBE-beta-CD that stabilized the complex. CCB showed limited cytotoxic activity on A549 cell lines. Complexation significantly increased activity passing from 30% to 45% cell mortality. Moreover, CCB/SBE-beta-CD strongly improved the cytotoxicity of GEM, observing about 60% of cell mortality for the combined formulation.

引用

页码：792 / 800

页数：9

共 67 条

[1] Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer [J].